Free Trial
→ America's AI Future Needs a Domestic Fuel Chain (From i2i Marketing Group, LLC) (Ad)tc pixel Free RUA Stock Alerts

RUA Life Sciences (RUA) Competitors

RUA Life Sciences logo
GBX 19.05 -0.59 (-3.00%)
As of 11:54 AM Eastern
Compare

RUA vs. IUG, NCYT, IHC, AVO, and MHC

Should you buy RUA Life Sciences stock or one of its competitors? MarketBeat compares RUA Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RUA Life Sciences include Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and MyHealthChecked (MHC). These companies are all part of the "medical devices" industry.

How does RUA Life Sciences compare to Intelligent Ultrasound Group?

RUA Life Sciences (LON:RUA) and Intelligent Ultrasound Group (LON:IUG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

RUA Life Sciences has a beta of 0.968, indicating that its share price is 3% less volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

RUA Life Sciences has a net margin of -3.26% compared to Intelligent Ultrasound Group's net margin of -23.11%. RUA Life Sciences' return on equity of -2.03% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Intelligent Ultrasound Group Neutral

Intelligent Ultrasound Group has higher revenue and earnings than RUA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M2.87-£2.66MN/AN/A
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

0.1% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. 7.3% of RUA Life Sciences shares are owned by company insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Intelligent Ultrasound Group beats RUA Life Sciences on 5 of the 9 factors compared between the two stocks.

How does RUA Life Sciences compare to Novacyt?

RUA Life Sciences (LON:RUA) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

RUA Life Sciences has a beta of 0.968, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Novacyt has a beta of 0.973, meaning that its stock price is 3% less volatile than the broader market.

In the previous week, Novacyt had 1 more articles in the media than RUA Life Sciences. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for RUA Life Sciences. Novacyt's average media sentiment score of 0.13 beat RUA Life Sciences' score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.

Company Overall Sentiment
RUA Life Sciences Neutral
Novacyt Neutral

RUA Life Sciences has a net margin of -3.26% compared to Novacyt's net margin of -135.96%. RUA Life Sciences' return on equity of -2.03% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Novacyt -135.96%-121.30%-27.98%

0.1% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 7.3% of RUA Life Sciences shares are owned by insiders. Comparatively, 0.7% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

RUA Life Sciences has higher earnings, but lower revenue than Novacyt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M2.87-£2.66MN/AN/A
Novacyt£20.03M1.40-£36.80M-£32.00N/A

Summary

RUA Life Sciences and Novacyt tied by winning 6 of the 12 factors compared between the two stocks.

How does RUA Life Sciences compare to Inspiration Healthcare Group?

Inspiration Healthcare Group (LON:IHC) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

7.4% of Inspiration Healthcare Group shares are held by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are held by institutional investors. 8.4% of Inspiration Healthcare Group shares are held by company insiders. Comparatively, 7.3% of RUA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Inspiration Healthcare Group has a beta of 0.717, indicating that its stock price is 28% less volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.968, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, Inspiration Healthcare Group had 1 more articles in the media than RUA Life Sciences. MarketBeat recorded 1 mentions for Inspiration Healthcare Group and 0 mentions for RUA Life Sciences. Inspiration Healthcare Group's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
Inspiration Healthcare Group Neutral
RUA Life Sciences Neutral

RUA Life Sciences has a net margin of -3.26% compared to Inspiration Healthcare Group's net margin of -25.32%. RUA Life Sciences' return on equity of -2.03% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Inspiration Healthcare Group-25.32% -69.35% -3.47%
RUA Life Sciences -3.26%-2.03%-17.50%

RUA Life Sciences has lower revenue, but higher earnings than Inspiration Healthcare Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspiration Healthcare Group£45.20M0.52-£12.20M-£13.65N/A
RUA Life Sciences£4.11M2.87-£2.66MN/AN/A

Summary

Inspiration Healthcare Group beats RUA Life Sciences on 6 of the 11 factors compared between the two stocks.

How does RUA Life Sciences compare to Advanced Oncotherapy?

Advanced Oncotherapy (LON:AVO) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Advanced Oncotherapy has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.968, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, Advanced Oncotherapy's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
Advanced Oncotherapy Neutral
RUA Life Sciences Neutral

RUA Life Sciences has higher revenue and earnings than Advanced Oncotherapy.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A
RUA Life Sciences£4.11M2.87-£2.66MN/AN/A

Advanced Oncotherapy has a net margin of 0.00% compared to RUA Life Sciences' net margin of -3.26%. RUA Life Sciences' return on equity of -2.03% beat Advanced Oncotherapy's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced OncotherapyN/A -67.34% -11.73%
RUA Life Sciences -3.26%-2.03%-17.50%

17.8% of Advanced Oncotherapy shares are held by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are held by institutional investors. 47.5% of Advanced Oncotherapy shares are held by insiders. Comparatively, 7.3% of RUA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

RUA Life Sciences beats Advanced Oncotherapy on 5 of the 9 factors compared between the two stocks.

How does RUA Life Sciences compare to MyHealthChecked?

RUA Life Sciences (LON:RUA) and MyHealthChecked (LON:MHC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

MyHealthChecked has lower revenue, but higher earnings than RUA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M2.87-£2.66MN/AN/A
MyHealthChecked£3.22M1.48-£1.04M-£3.76N/A

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled MyHealthChecked'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
MyHealthChecked Neutral

RUA Life Sciences has a net margin of -3.26% compared to MyHealthChecked's net margin of -60.34%. RUA Life Sciences' return on equity of -2.03% beat MyHealthChecked's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
MyHealthChecked -60.34%-30.82%-8.18%

RUA Life Sciences has a beta of 0.968, indicating that its stock price is 3% less volatile than the broader market. Comparatively, MyHealthChecked has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

0.1% of RUA Life Sciences shares are held by institutional investors. Comparatively, 0.7% of MyHealthChecked shares are held by institutional investors. 7.3% of RUA Life Sciences shares are held by insiders. Comparatively, 9.3% of MyHealthChecked shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

MyHealthChecked beats RUA Life Sciences on 6 of the 10 factors compared between the two stocks.

Get RUA Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RUA vs. The Competition

Export
MetricRUA Life SciencesMedical Devices IndustryMedical SectorLON Exchange
Market Cap£11.82M£2.13B£6.45B£2.74B
Dividend Yield1.44%2.66%2.67%6.16%
P/E Ratio-2.6114.5023.92366.44
Price / Sales2.87125.60480.9087,084.75
Price / Cash2.4015.9926.9927.85
Price / Book0.894.4710.367.67
Net Income-£2.66M£144.75M£3.57B£5.89B
7 Day Performance4.67%-2.91%-1.11%-0.92%
1 Month Performance-19.42%-3.00%3.40%1.58%
1 Year Performance57.11%-0.80%23.87%72.44%

RUA Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RUA
RUA Life Sciences
N/AGBX 19.05
-3.0%		N/A+62.0%£11.82M£4.11MN/A48
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
NCYT
Novacyt
N/AGBX 42.18
+5.2%		N/A-17.0%£30.56M£20.03MN/A120
IHC
Inspiration Healthcare Group
N/AGBX 26.20
+2.3%		N/A+19.1%£23.49M£45.20MN/A224
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/AN/A3,900

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:RUA) was last updated on 6/8/2026 by MarketBeat.com Staff.
From Our Partners
America's AI Future Needs a Domestic Fuel Chain
AI dominance requires power at a scale most investors have not priced in - and nuclear energy is emerging as a...
i2i Marketing Group, LLC | Sponsoredtc pixel
Tiny Nasdaq Firm Lands €13.9 Million Semiconductor Deal
One small Nasdaq-listed company just landed a 13.9 million euro contract tied to a new advanced-node semicondu...
Finplays | Sponsoredtc pixel
BNZI Breakout Watch: AI Growth Meets Turnaround Setup!
Banzai International (NASDAQ: BNZI) posted full-year 2025 revenue of $12.2 million, up 169% year-over-year, wi...
Huge Alerts | Sponsoredtc pixel
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...
Porter & Company | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your name isn't on our protected list yet
I checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...
American Alternative | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel